Clinical Trial Search

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index Score ≥75% (PASI 75) Improvement (Efficacy of Baricitinib in Participants With Moderate to Severe…

Primary: Difference Between ABI (Ankle - Brachial Index) Before Electrical Cardioversion Using Two Methods (Doppler and Oscillometric). — 1.21; 1.215; 1.14; 1.18 ratio — p=<0.05

Primary: Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate) — 4; 0; 3; 1 participants

Primary: Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From…

Primary: Number of Participants Who Could Tolerate Twice Daily Oxytocin — 13; 11 Participants

Primary: Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912) — 22; 39; 43 percentage of participants

Primary: Number of Participants With Best Clinical Response (Core) — 0 Participants

Primary: Proportion of Subjects Achieving ≥5% Weight Loss at 16 Weeks Compared to Week 0 — 12 Participants

Primary: The Efficacy Rate Based on the Overall Colon Cleansing Effect as Assessed by the Independent Central Judging Committee Using the Japanese Colon Cleansing Scale — 97.7…

Primary: Percent Change in Mean Arterial Pressure (MAP) — 26.7; 30.8; 26.5; 24.5 % change

Primary: Change From Baseline in Participant Glucose When Fasting and Fed — 83.3; -8.0; 5.9 mg/dL

Primary: Number of Participants WithTreatment-Related Adverse Events — 73 Participants

Primary: Mean Change in Systolic Blood Pressure — -14.4; -11.3; 162.2; 160.7 mmHg — p=0.60

Primary: Maximum Drug Concentration During the Selected Dosing Interval (Cmax) After a Single Dose — 1889.579; 1844.423 Nanogram per milliliter — p=0.4396

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died — 0; 0; 1; 1 participants